Sign in Subscribe

article

A collection of 632 issues

Patients With Poor Performance Status Still Benefit From Immunotherapy in MSI-H CRC

Skip to content The CRC Digest ▸ TREATMENT Patients With Poor Performance Status Still Benefit From Immunotherapy in MSI-H CRC An international retrospective study of dMMR/MSI-H metastatic colorectal cancer patients found that immune checkpoint blockers produced durable responses even in patients with poor ECOG performance status, a group often excluded

Immunotherapy Compared to Standard Care in MSS Metastatic CRC

Skip to content The CRC Digest ▸ TREATMENT Immunotherapy Compared to Standard Care in MSS Metastatic CRC A propensity-matched analysis of 708 chemorefractory patients compared immune checkpoint inhibitors to standard treatments like trifluridine/tipiracil in microsatellite stable metastatic colorectal cancer, though ICIs have limited efficacy in this population and selected patients

Russian registry study reports MSI/dMMR prevalence in 2,101 consecutive colorectal cancer patients

Skip to content The CRC Digest ◇ RESEARCH Russian registry study reports MSI/dMMR prevalence in 2,101 consecutive colorectal cancer patients A prospective multicenter registry enrolled consecutive, unselected patients with primary colorectal adenocarcinoma at six Moscow centers between 2022 and 2025 to establish population-level data on mismatch repair deficiency prevalence

Single-cell study identifies ETV4-MC1R pathway driving immunotherapy resistance in MSI-H CRC

Skip to content The CRC Digest ◇ RESEARCH Single-cell study identifies ETV4-MC1R pathway driving immunotherapy resistance in MSI-H CRC Researchers used single-cell RNA sequencing to compare PD-1-resistant and PD-1-sensitive MSI-H metastatic colorectal tumors, identifying a gene regulatory network involving ETV4 and MC1R that may explain why some MSI-H cancers don'

AI-assisted colonoscopy cost-effectiveness study evaluates financial impact in Singapore

Skip to content The CRC Digest ▪ SCREENING AI-assisted colonoscopy cost-effectiveness study evaluates financial impact in Singapore Computer-assisted detection (CADe) during screening colonoscopy improves adenoma detection rates while reducing endoscopists' mental fatigue. (Int J Surg) This content is informational only and does not constitute medical advice. Always consult your oncologist

Case series from Tanzania documents colorectal cancer in patients under 30

Skip to content The CRC Digest ♥ LIVING WITH CRC Case series from Tanzania documents colorectal cancer in patients under 30 Three patients under age 30 presented with advanced disease after prolonged symptoms including rectal bleeding and weight loss; two had mucinous adenocarcinoma and one had a family history suggesting hereditary

Direct inhibitors for KRAS G12D and G12V mutations now in development for colorectal cancer

Skip to content The CRC Digest ◇ RESEARCH Direct inhibitors for KRAS G12D and G12V mutations now in development for colorectal cancer While approved KRAS therapies target only the rare G12C mutation, new drugs including MRTX1133, zoldonrasib, and daraxonrasib are being developed to directly target G12D and G12V—the most common

First Colombian report of MUTYH-associated polyposis with novel mutations

Skip to content The CRC Digest ◇ RESEARCH First Colombian report of MUTYH-associated polyposis with novel mutations Case series from Colombia's Tolima Grande region describes individuals carrying pathogenic MUTYH variants c.452A>G and c.1353_1355del associated with polyposis phenotypes and colorectal cancer predisposition. (Frontiers in Oncology)

CRISPR-Cas9 electroporation targets KRAS G12V mutation in CRC cells

Skip to content The CRC Digest ◇ RESEARCH CRISPR-Cas9 electroporation targets KRAS G12V mutation in CRC cells Researchers used direct electroporation of Cas9 ribonucleoproteins to achieve allele-specific disruption of KRAS p.G12V in SW480 colorectal cancer cells, assessing delivery efficiency and on-target editing. (Iranian Journal of Basic Medical Sciences) This content

Bispecific antibody co-targeting EGFR and CDH17 reduces skin toxicity in preclinical CRC models

Skip to content The CRC Digest ◇ RESEARCH Bispecific antibody co-targeting EGFR and CDH17 reduces skin toxicity in preclinical CRC models A bispecific antibody co-targeting EGFR and cadherin-17 (CDH17) achieved superior tumor growth inhibition compared to EGFR- or c-MET/EGFR-targeting antibodies while reducing skin-related toxicities in preclinical colorectal cancer studies. The